Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

A Study Revealed That A New Vasculitis Treatment May Be As Good As Standard Therapy

 



(Medical-NewsWire.com, May 28, 2015 ) Orlando, FL -- Vasculitis can cause people to suffer from a variety of symptoms such as headache, fever, weight loss, fatigue, night sweats, rash and nerve problems. However, it seems that sufferers are getting close to having a helpful treatment.

A study revealed that a new vasculitis treatment may be as good as standard therapy. This condition is uncommon and is characterized by the inflammation of blood vessels. Treatment is often focused on decreasing blood vessel inflammation and enhancing the function of the organs affected.

The New England Journal of Medicine published a study that found the biologic drug rituximab works well in controlling a type of vasculitis. The treatment involved four weekly infusions of the drug, which was believed to be equivalent to an 18-month daily intake of immunosuppressive pills.

Ulrich Specks, M.D., chair of the division of pulmonary and critical care medicine at the Mayo Clinic, believes that it's a game changer. He added that having a good alternative to traditional medicine would be very good news.

According to The Arthritis Foundation, vasculitis is an autoimmune disease that takes place when the body mistakenly considers the blood vessels as foreign invaders, and thus attacks them. This causes inflammation and eventually a narrowing of the vessels. Severe cases of vasculitis often make patients suffer from organ damage or even death. Although there are many types of vasculitis, the one examined by the study is known as the antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

"There are times when vasculitis is successfully treated. However, it can recur and never really goes away. There are even times when it requires long-term, ongoing treatment," said VitaBreeze Supplements spokesperson, Michelle O'Sullivan.

Rituximab is a biologic drug that works by depleting B-cells, which are a type of white blood cell. It is often used as a treatment for rheumatoid arthritis, some blood cancers and other conditions. The Food and Drug Administraion (or FDA) has approved rituximad in 2011 as the first new treatment for AAV.

Many rheumatoid arthritis patients use drugs such as Rituximab, but there are also those who use natural supplements such as curcumin. Vasculitis and arthritis have things in common and one is inflammation. However, for many arthritis patients inflammation can be properly addressed with the use of treatments such as curcumin.

Curcumin, which is a key ingredient of turmeric, contains antioxidant, anti-inflammatory and anti-bacterial properties. It is believed to be effective in helping patients achieve pain relief and improved mobility (http://www.amazon.com/Turmeric-Curcumin-Complex-BioPerine-Bio-availability/dp/B00JA4TLTI/).


About VitaBreeze

VitaBreeze is a nutraceutical brand that manufactures high quality natural supplements to help people live a healthy, enjoyable and longer life.

VitaBreeze

Benjamin Lasance

(407) 545-2239

media@vitabreeze.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC